Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics
December 20, 2011
-
REGULATORY MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts
December 19, 2011
-
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development
December 19, 2011
-
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April
December 16, 2011
-
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery
December 15, 2011
-
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
-
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use
December 15, 2011
-
BUSINESS MTPC to Focus on Development of Global Human Resources
December 14, 2011
-
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
-
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision
December 13, 2011
-
REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs
December 12, 2011
-
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development
December 9, 2011
-
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs
December 8, 2011
-
BUSINESS Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals
December 7, 2011
-
BUSINESS Growth for All Products Is Indispensable: President Alvarez of MSD
December 7, 2011
-
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years
December 7, 2011
-
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales
December 6, 2011
-
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”
December 6, 2011
-
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut
December 5, 2011
-
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report
December 2, 2011
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…